Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Event Participation - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference [1] - The conference will take place from April 7-10, 2025, with Verrica's session scheduled for April 8, 2025, at 1:30 pm ET [2] - Participants can access a live webcast of the event through Verrica's website, with a replay available for 90 days post-event [2]